Form 4 for HURA TuHURA Biosciences, Inc./NV
Accepted 2022-02-17 00:00:00 ET · period of report 2022-02-15 · accession 0000905718-22-000393 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-17 | 2022-02-15 | HURA | Hoffman Robert E. | Pres, CEO, Dir | P - Purchase | $0.47 | +55.0K | 55.0K | New | +$25.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-15 | P | A | 55,000 | $0.47 | 55,000 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4625 to $0.4697 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |